Skip to main content

Media Alert – Investment Announcement!

August 10th 2023 – Birmingham, Michigan – CitySide Ventures and GLAF announce adding SciTech to its portfolio of companies.

CitySide Ventures Grate Lakes Angels Fund participated in the companys’ $2.5M Seed round. 

SciTech is a clinical stage, biopharmaceutical company that has developed a proprietary nano-delivery system (SciTech Drug Delivery Platform – SDP) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug or active pharmaceutical ingredient (API) is fenretinide, the API in SciTech’s lead drug candidate, has been shown in numerous clinical trials to be a relatively safe and effective anticancer therapy with targeted cancer destroying activity. The patented combination of the new SDP and fenretinide has led to SciTech’s first drug candidate, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives.

We are pleased that they have not only had a production run and it met FDA requirements, the drug is safe, UPMC has signed on as the 1st clinical test site – these are some of the de-risking they have achieved thus far.  Looks very promising!   – David Weaver – President Emeritus, CitySide Ventures 

CitySide Ventures is to become a premier Investment group committed to taking Michigan Angel investing to a new level by building a network of active, progressive, and innovative investors committed to turning Michigan into a powerhouse startup ecosystem.

For more information about Birmingham Angels please visit us at

For more information about Great Lakes Angels Fund please visit us at

If you are an accredited investor and would like to schedule a private meeting,

please complete the following request form:

or contact us: or 248. 535.1306